Table 2.
Objective response by mRECIST predicts OS: results of RCTs
| First author [ref.], year | Agents (study design) | ORR (mRECIST), %(n/total n) | Median OS, months |
HR (95% CI) | p value | |
|---|---|---|---|---|---|---|
| Responder (CR + PR) |
Nonresponder (SD+ PD) |
|||||
| Lencioni [6], 2017 | Brivanib (phase 3 RCT) |
11.5 (26/226) | 14.3 | 9.4 | 0.31 (0.16–0.60) |
<0.001 |
| Meyer [7], 2017 | nintedanib +sorafenib | 15.6 (28/180) | 16.7 | 10.9 | 0.544 (0.335–0.881) |
0.0122 |
| (phase 2 RCT) | ||||||
| Kudo [8], 2018 | sorafenib | 18.8 (18/96) | 27.2 | 8.9 | N/A | <0.001 |
| (phase 3 RCT) | ||||||
OS, overall survival; RCT, randomized controlled trial; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; N/A, not available.